Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01193452
Recruitment Status : Unknown
Verified August 2010 by Fudan University.
Recruitment status was:  Recruiting
First Posted : September 2, 2010
Last Update Posted : September 2, 2010
Information provided by:
Fudan University

Brief Summary:
This phase II trial on the assumption that S-1 combined with Leucovorin may have better efficacy and safety than simplified 5-FU/LV infusion therapy in elderly patients with advanced colorectal cancer.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Drug: S-1, Leucovorin Drug: leucovorin, 5-fluorouracil Phase 2

Detailed Description:
This is a randomized phase Ⅱ study, in which S-1 is used in combination with leucovorin in elderly patients with advanced colorectal cancer as first-line treatment,comparing with sLV5FU2 therapy. The aim of this study is to determine the efficacy and safety of S-1/LV in elderly patients in the first-line setting. The other secondary endpoints are progression free survival,overall survival, and quality of life are also evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase II Study of Comparing S-1/Leucovorin With sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer
Study Start Date : August 2010
Estimated Primary Completion Date : February 2011
Estimated Study Completion Date : February 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: S-1/LV
S-1 combined with Leucovorin
Drug: S-1, Leucovorin

S-1 :

The initial dosage of S-1 is determined by the body surface area:

Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day


25mg twice per day po.

The treatment is given for one week,and no chemotherapy is given for the following one week.

Other Name: chemotherapy

Active Comparator: sLV5FU2
5-FU/LV infusion
Drug: leucovorin, 5-fluorouracil

leucovorin: 400mg/m2 intravenous infusion d1;

5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours

repeat every 2 weeks

Other Name: chemotherapy

Primary Outcome Measures :
  1. response rate [ Time Frame: six weeks ]

Secondary Outcome Measures :
  1. progression free survival [ Time Frame: six weeks ]
  2. disease control rate [ Time Frame: six weeks ]
  3. time to treatment failure [ Time Frame: six weeks ]
  4. overall survival [ Time Frame: three months ]
  5. quality of life [ Time Frame: six weeks ]
  6. Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: six weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Signed written informed consent
  • Oral medication is acceptable
  • Histologically confirmed colorectal carcinoma
  • Male or female ≥ 65 years of age
  • No prior chemotherapy,radiotherapy,target therapy and immunotherapy, except adjuvant chemotherapy with an interval of ≥ 180 days)
  • Presence of at least one target lesion measurable by CT scan or MRI,within 15 days prior to trial
  • The lab values within 2 weeks prior to trial should meet:

PLT ≥7.5*10^4/mm3 ANC≥2000/mm3 HB≥100g/L Total bilirubin < upper limit of normal level ALT/AST/ALP < 2.5 x UNL (<5 x UNL for patients with liver or bone metastasis) Serum creatinine < UNL

  • Performance status (ECOG) 0~1
  • Life expectation longer than 90 days

Exclusion Criteria:

  • Allergy to S-1,fluorouracil or leucovorin
  • Any investigational agent(s) within 4 weeks prior to entry
  • Previous or currently exposure to certain drugs which are proved to have influence on blood drug concentration
  • Active infection
  • Severe organ failures or diseases, including: intestinal obstruction, pulmonary fibrosis, uncontrolled diabetes mellitus,clinically relevant coronary disease, cardiovascular disorder or myocardial infarction,renal or liver failure, severe psychiatric illness,cerebral vascular disease and sever GI ulcer which need blood infusion.
  • Uncontrolled hydrothorax,ascites and hydropericardium
  • Multiple bone metastatic lesions
  • Brain metastases
  • Chronic diarrhea or digestive disfunction
  • Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
  • Strong willingness to receive surgery or highly potential to have intestinal obstruction which may need surgery intervention
  • Other conditions that primary investigate or investigator consider to be unsuitable for the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01193452

Layout table for location contacts
Contact: Jin Li, MD,PhD 64175590 ext 5100
Contact: Wenhua Li, MS 64175590 ext 8900

Layout table for location information
China, Shanghai
Jin Li` Recruiting
Shanghai, Shanghai, China, 200032
Contact: Jin Li, MD,PhD    8621 64175590 ext 5100      
Contact: Wenhua Li, MS    862164175590 ext 8900   
Sub-Investigator: Wen Zhang         
Sponsors and Collaborators
Fudan University
Layout table for investigator information
Principal Investigator: Jin Li, MD,PhD Fudan University

Layout table for additonal information
Responsible Party: Jin Li, Fudan University Shanghai Cancer Center Identifier: NCT01193452    
Other Study ID Numbers: SL-eCRC
First Posted: September 2, 2010    Key Record Dates
Last Update Posted: September 2, 2010
Last Verified: August 2010
Keywords provided by Fudan University:
elderly patients
advanced colorectal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs